Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Chia Jui Yen

Citation

Annals of Oncology (2015) 26 (suppl_9): 93-102. 10.1093/annonc/mdv527

Authors

C.J. Yen1, A. Klochikhin2, E.E.W. Cohen3, J. Vermorken4, K. Harrington5, M. Tahara6, J.Y. Ge7, J. Geib7, F. Jin7, B. Burtness8

Author affiliations

  • 1 Internal Medicine, National Cheng Kung University Hospital, 704 - Tainan/TW
  • 2 Oncology, Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl/RU
  • 3 Translational Science, University of California at San Diego, Moores Cancer Center, San Diego/US
  • 4 Medical Oncology, Antwerp University Hospital, Edegem/BE
  • 5 Medical Oncology, Institute of Cancer Research, London/GB
  • 6 Medical Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 7 ,, Merck & Co., Inc., Kenilworth/US
  • 8 Yale Cancer Center, Yale University, New Haven/US
More

Resources

Abstract 1224

Background

Cetuximab plus platinum and 5-fluorouracil (5-FU) is the only combination regimen recommended by current guidelines as the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Given the regimen's toxicities, there is unmet medical need in this area. Colocalization of T cells expressing programmed death-1 (PD-1) receptor and tumor cells expressing its ligands, PD-L1 and PD-L2, facilitates immune evasion in HNSCC. Pembrolizumab is a potent and highly selective humanized monoclonal antibody that directly blocks the interaction of PD-1 and each of its ligands; preliminary data from the KEYNOTE-012 trial suggest that durable response is demonstrated by pembrolizumab for R/M HNSCC patients.

Trial design

This is a randomized, active-controlled, open-label, phase 3 trial to determine the efficacy and safety of pembrolizumab as monotherapy or in combination with chemotherapy relative to standard of care in patients with first-line R/M HNSCC (ClinicalTrials.gov, NCT02358031). Key inclusion criteria were confirmed R/M HNSCC considered incurable by local therapies, no prior systemic therapy in the R/M setting, ECOG 0 or 1, and tumor biopsy tissue for PD-L1 biomarker analysis. Approximately 780 patients will be enrolled and randomly assigned 1:1:1 to (i) pembrolizumab, (ii) pembrolizumab + platinum + 5-FU, or (iii) cetuximab + platinum + 5-FU. Pembrolizumab, 5-FU, and cetuximab will be administered at doses of 200 mg every 3 weeks (Q3W), 1000 mg/m2/day over 4 days Q3W, and 400 mg/m2 (initial load) then 250 mg/m2 every week, respectively; platinum therapy will comprise cisplatin 100 mg/m2 Q3W or carboplatin AUC 5 mg/mL/min Q3W. Patients will be stratified according to PD-L1 expression status, ECOG PS, and HPV status. The primary endpoint is progression-free survival per RECIST 1.1 as assessed by central radiologist review. Secondary endpoints were overall survival, proportion progression free at 6 and 12 months, overall response rate, and response duration. Relative pharmacokinetics and safety/tolerability profile of pembrolizumab alone or in combination with chemotherapy will also be evaluated.

Clinical trial identification

NCT02358031

Disclosure

A. Klochikhin: research: Merck. J. Vermorken: advisory board: Merck Serono, Boehringer-Ingelheim, Vaccinogen, Synthon Pharmaceuticals, Innate Pharma, Pierre Fabre, Debiopharm, Glycotope. J.Y. Ge, J. Geib, F. Jin: employee, Merck & Co., Inc. B. Burtness: advisory board: Merck, VentiRx, Amgen, Bayer, Boehringer-Ingelheim. Research: Genentech, Koltan Pharmaceuticals, Merck. Expert witness: Johnson & Johnson. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings